Positive CHMP opinion on the marketing authorization of elacestrant for patients with HR+/HER2- MBC with detectable ESR1 mutations. The first oral SERD gets closer to Europe.
For details: Click here
Source: Paolo Tarantino/Twitter
Positive CHMP opinion on the marketing authorization of elacestrant for patients with HR+/HER2- MBC with detectable ESR1 mutations. The first oral SERD gets closer to Europe.
For details: Click here
Source: Paolo Tarantino/Twitter